Professional Documents
Culture Documents
RESULTS. Of 506 patients (median age 5 56.2 years), 347 (68.6%) had stage I and
1
Department of Obstetrics and Gynecology, Columbia University, New York, New York.
5
159 (31.4%) had stage II cancers. The 5-year recurrence-free (RFS) and overall survivals (OS) were 75.5% and 81.7%, respectively. On multivariate analysis, older age,
higher stage, higher grade, and malignant cytology were independent prognostic
factors predictive for recurrence and poorer survival. The risk of recurrence was
higher for those !60 versus < 60 years (hazards ratio [HR] 5 1.57, 95% confidence
interval [CI], 1.122.19), stage II (stage II: HR 5 2.70, 95% CI, 1.415.16) versus
stage IA or IB, grade 2 (HR 5 1.84, 95% CI, 1.043.27) and grade 3 (HR 5 2.47, 95%
CI, 1.394.37) versus grade 1, and positive versus negative cytology (HR 5 1.72,
95% CI, 1.212.45). By using these factors in a prognostic index, those with lowrisk (no or 1 risk factor), intermediate-risk (2 factors), and high-risk (34 risk factors) disease had survivals of 88%, 82%, and 75%, respectively (P < .05).
CONCLUSIONS. Age, stage, grade, and cytology are important prognostic factors in highrisk early-stage epithelial ovarian cancer. This information may be used in the design
of future clinical trials. Cancer 2008;112:220210. ! 2008 American Cancer Society.
DOI 10.1002/cncr.23390
Published online 17 March 2008 in Wiley InterScience (www.interscience.wiley.com).
2203
RESULTS
Of the 506 patients included in this analysis, the median age at diagnosis was 56 years (range, 2288
2204
CANCER
TABLE 1
Patient and Clinicopathologic Characteristics (N 5 506)
Age, y
< 50
5059
6069
!70
Median [range]
Race
White
Black
Hispanic
Other
Performance status
0
1
2
FIGO stage
IA
IB
IC
IIA
IIB
IIC
Histology
Serous
Endometrioid
Clear cell
Mucinous
Other
Tumor grade*
1
2
3
Not graded, clear cell
Presence of Ascites
Yes
No
Cytology
Positive
Suspicious
Negative
Unknown
Ruptured tumor
Yes
No
Treatmenty
Protocol 95 32P
Protocol 95 CP
Protocol 157 PC (3)
Protocol 157 PC (6)
No. of patients
152
146
123
85
56
30.0
28.6
24.3
16.8
[2588]
451
20
21
14
89.1
4.0
4.2
2.8
264
222
20
52.2
43.9
4.0
69
10
268
43
28
88
13.6
2.0
53.0
8.5
5.5
17.4
108
134
137
50
77
21.3
26.5
27.1
9.9
15.2
95
127
147
137
18.8
25.1
29.1
27.1
153
353
30.2
69.8
125
23
340
12
25.0
4.6
68.0
2.4
219
287
43.3
56.7
98
107
155
146
19.4
21.1
30.6
28.9
% 5-year
RFS
% 5-year
OS
Disease recurrence
80.1
68.5
.004
84.8
77.1
<.001
451
55
74.9
80.9
.29
82.6
73.7
.96
264
242
76.4
74.2
.47
81.7
81.6
.24
87.1
77.8
65.9
.001
108
134
137
50
77
66.4
75.6
79.6
85.9
73.9
.16
95
127
147
137
85.1
73.4
67.4.
79.6
153
353
85.9
83.7
76.2
Death
HR
95% CI
HR
95% CI
1.0
1.57
1.122.19
.009
1.0
1.96
1.412.71
<.001
1.0
1.74
2.70
0.913.33
1.415.16
.003
1.0
1.54
2.36
0.852.79
1.304.27
.005
1.0
1.84
2.47
1.66
1.043.27
1.394.37
0.913.04
.02
1.0
1.23
1.86
1.46
0.722.09
1.103.15
0.852.50
.09
1.0
1.72
1.212.45
.003
1.0
1.53
1.092.16
.02
302
204
79
268
159
TABLE 3
Multivariate Analysis of Prognostic Factors for Recurrence-free
Survival (RFS) and Overall Survival (OS) (N 5 506)
OS
2205
.009
79.3
83.7
81.5
83.7
80.5
.47
.01
85.9
81.6
79.2
81.5
.10
71.4
77.3
.05
81.3
81.9
.58
148
358
67.0
78.9
<.001
75.5
84.2
.01
219
287
76.8
74.5
.22
83.1
80.6
.59
98
107
155
146
66.8
77.2
76.3
79.2
.08
77.3
84.0
80.3
84.5
.44
Age, y
< 60
!60
Stage
IA or IB
IC
II
Tumor grade*
1
2
3
Not graded, clear cell
Cytology
Negative
Positive
years versus age < 60 years was 1.57 (95% confidence interval [CI], 1.122.19). The risk for recurrence was increased with advanced stage of disease
(stage II: hazard ratio [HR] 5 2.70, 95% CI, 1.415.16,
relative to stage IA or IB). In addition, patients with
grade 2 (HR 5 1.84, 95% CI, 1.043.27) and grade 3
(HR 5 2.47, 95% CI, 1.394.37) tumors were at
increased risk for disease recurrence compared with
grade 1 cancers. Women with positive cytology had a
significantly elevated risk for disease recurrence compared with those with negative cytology (HR 5 1.72,
95% CI, 1.212.45). Because the clear-cell patients
were not graded and all stage IA or IB patients
selected had grade 3 tumors, the results on tumor
grade above may not well reflect the effect of tumor
grade on prognosis. Further analysis restricted to
stage IC, stage II, excluding clear-cell patients was
conducted. The 5-year RFS was estimated to be
85.1%, 73.4%, and 62.6% for grade 1, grade 2, and
grade 3, respectively. The adjusted HR was 1.89 (95%
CI, 1.063.35) for grade 2 and 2.55 (95% CI, 1.42
4.59) for grade 3 compared with tumor grade 1, confirming the significance of tumor grade on disease
recurrence. All other variables (race, performance
status, histology, tumor rupture, and ascites) were
not significantly associated with RFS. The results on
OS were similar. These findings were consistent in
the OS analyses.
Figures 1 to 4 demonstrate the Kaplan-Meier
estimate of RFS and OS by age group, stage of dis-
2206
CANCER
ease, tumor grade, and cytology. Among the prognostic parameters, these independent prognostic factors
were used to develop a prognostic index for potential
clinical application. The prognostic model for RFS is
based on the 4 risk factors: age !60 years (vs
age < 60 years), stage II disease (vs stage I disease),
positive cytology (vs negative cytology), and grade 2
3 tumors or clear cell (vs grade 1 disease). Low-risk
patients were defined as those with no or 1 risk factor; intermediate-risk patients as those with any 2
risk factors; and high-risk patients as women with
any 3 or 4 risk factors. The 5-year RFS of the low-,
intermediate-, and high-risk groups was estimated to
be 88%, 71%, and 62%, respectively. On the basis of
the number of risk factors, patients in the low-, intermediate-, and high-risk groups had corresponding
OSs of 88%, 82%, and 75% (P < .05) (Fig. 5A,B).
DISCUSSION
Early-stage ovarian cancer patients constitute a heterogeneous group with respect to risk of recurrence
and survival. Prior reports have shown that patients
with early-stage disease have overall survivals ran-
2207
2208
CANCER
tumors or clear cell). Low-risk: 0"1 risk factors; mid-risk: 2 risk factors;
high-risk: 3"4 risk factors (P < .001). (B) Kaplan-Meier overall survival by
number of risk factors (P < .001).
REFERENCES
1.
2209
11. Finn CB, Luesley DM, Buxton EJ, et al. Is stage I epithelial
ovarian cancer overtreated both surgically and systemically? Results of a 5-year cancer registry review. Br J Obstet
Gynaecol. 1992;99:5458.
12. Vergote IB, Kaern J, Abeler VM, et al. Analysis of prognostic
factors in stage I epithelial ovarian carcinoma: importance
of degree of differentiation and deoxyribonucleic acid ploidy
in predicting relapse. Am J Obstet Gynecol. 1993;169:4052.
13. Bertelsen K, Holund B, Andersen JE, et al. Prognostic factors and adjuvant treatment in early epithelial ovarian cancer. Int J Gynecol Cancer. 1993;3:211218.
14. Sjovall K, Nilsson B, Einhorn N. Different types of rupture
of the tumor capsule and the impact on survival in early
ovarian carcinoma. Int J Gynecol Cancer. 1994;4:333336.
15. Ahmed FY, Wiltshaw E, AHern RP, et al. Natural history
and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol. 1996;14:29682975.
16. Trope C, Kaern J, Hogberg T, et al. Randomized study on
adjuvant chemotherapy in stage I high-risk ovarian cancer
with evaluation of DNA-ploidy as prognostic instrument.
Ann Oncol. 2000;11:281288.
17. Bell J, Brady MF, Young RC, et al. Randomized phase III
trial of 3 versus 6 cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2006;102:432439.
18. Travis LB, Holowaty EJ, Bergfeldt K, et al. Risk of leukemia
after platinum-based chemotherapy for ovarian cancer.
N Engl J Med. 1999;340:351357.
19. Young RC, Brady MF, Nieberg RK, et al. Adjuvant treatment
for early ovarian cancer: a randomized phase III trial of
intraperitoneal 32P or intravenous cyclophosphamide and
cisplatina gynecologic oncology group study. J Clin
Oncol. 2003;21:43504355.
20. Nguyen HN, Averette HE, Hoskins W, et al. National survey
of ovarian carcinoma. Part V. The impact of physicians
specialty on patients survival. Cancer. 1993;72:36633670.
21. Chan JK, Loizzi V, Lin YG, et al. Stages III and IV invasive
epithelial ovarian carcinoma in younger versus older
women: what prognostic factors are important? Obstet
Gynecol. 2003;102:156161.
22. Plaxe SC, Braly PS, Freddo JL, et al. Profiles of women age
3039 and age less than 30 with epithelial ovarian cancer.
Obstet Gynecol. 1993;81:651654.
23. Rodriguez M, Nguyen HN, Averette HE, et al. National survey of ovarian carcinoma XII. Epithelial ovarian malignancies in women less than or equal to 25 years of age.
Cancer. 1994;73:12451250.
24. Smedley H, Sikora K. Age as a prognostic factor in epithelial
ovarian carcinoma. Br J Obstet Gynaecol. 1985;92:839842.
25. Thigpen T, Brady MF, Omura GA, et al. Age as a prognostic
factor in ovarian carcinoma. The Gynecologic Oncology
Group experience. Cancer. 1993;71:606614.
26. Duska LR, Chang YC, Flynn CE, et al. Epithelial ovarian
carcinoma in the reproductive age group. Cancer. 1999;
85:2623269.
27. Massi D, Susini T, Savino L, et al. Epithelial ovarian tumors
in the reproductive age group: age is not an independent
prognostic factor. Cancer. 1996;77:1131116.
28. Chan JK, Urban R, Cheung MK, et al. Ovarian cancer in
younger vs older women: a population-based analysis. Br J
Cancer. 2006;95:13141320.
29. Nagele F, Petru E, Medl M, et al. Preoperative CA 125: an
independent prognostic factor in patients with stage I
epithelial ovarian cancer. Obstet Gynecol. 1995;86:259264.
2210
CANCER
30. Brugghe J, Baak JP, Wiltshaw E, et al. Quantitative prognostic features in FIGO I ovarian cancer patients without postoperative treatment. Gynecol Oncol. 1998;68:4753.
31. Du Bois A, Rochon J, Lamparter C, et al. Pattern of care and
impact of participation in clinical studies on the outcome in
ovarian cancer. Int J Gynecol Cancer. 2005;15:183191.
32. Mizuno M, Kikkawa F, Shibata K, et al. Long-term prognosis of stage I ovarian carcinoma. Prognostic importance of
intraoperative rupture. Oncology. 2003;65:2936.
33. Valverde JJ, Martin M, Garcia-Asenjo JA, et al. Prognostic
value of DNA quantification in early epithelial ovarian carcinoma. Obstet Gynecol. 2001;97:409416.
34. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy
with either single-agent carboplatin or cyclophosphamide,
doxorubicin, and cisplatin in women with ovarian cancer:
the ICON3 randomised trial. Lancet. 2002;360:505515.
35. Vergote I, De Brabanter J, Fyles A, et al. Prognostic importance of degree of differentiation and cyst rupture in stage
I invasive epithelial ovarian carcinoma. Lancet. 2001;357:
176182.
36. Skirnisdottir I, Seidal T, Sorbe B. A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial
ovarian carcinoma and avoiding the problem of inaccurate
surgical staging. Int J Gynecol Cancer. 2004;14:259270.
37. Trimbos JB, Vergote I, Bolis G, et al. Impact of adjuvant
chemotherapy and surgical staging in early-stage ovarian
carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst. 2003;95:113125.
38. Le T, Adolph A, Krepart GV, et al. The benefits of comprehensive surgical staging in the management of early-stage
epithelial ovarian carcinoma. Gynecol Oncol. 2002;85:351
355.
39. Zanetta G, Rota S, Chiari S, et al. The accuracy of staging:
an important prognostic determinator in stage I ovarian
carcinoma. A multivariate analysis. Ann Oncol. 1998;9:
10971101.
40. Rubin SC, Wong GY, Curtin JP, et al. Platinum-based chemotherapy of high-risk stage I epithelial ovarian cancer after comprehensive surgical staging. Obstet Gynecol. 1993;82: 143147.
41. Villa A, Parazzini F, Acerboni S, et al. Survival and prognostic factors of early ovarian cancer. Br J Cancer. 1998;77:
123124.
42. Bolis G, Colombo N, Pecorelli S, et al. Adjuvant treatment
for early epithelial ovarian cancer: results of 2 randomised
clinical trials comparing cisplatin to no further treatment
or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica. Ann Oncol.
1995;6:887893.
43. Sainz de la Cuesta R, Goff BA, Fuller AF Jr, et al. Prognostic
importance of intraoperative rupture of malignant ovarian
epithelial neoplasms. Obstet Gynecol. 1994;84:17.
44. Paramasivam S, Tripcony L, Crandon A, et al. Prognostic
importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial
ovarian cancer: an Australian multicenter study. J Clin
Oncol. 2005;23:59385942.
45. Keettel WC, Pixley E. Diagnostic value of peritoneal washings. Clin Obstet Gynecol. 1958;1:592606.
46. Morton DG, Moore JG, Chang N. The clinical value of peritoneal lavage for cytologic examination. Am J Obstet Gynecol. 1961;81:11151125.
47. Creasman WT, Rutledge F. The prognostic value of peritoneal cytology in gynecologic malignant disease. Am J
Obstet Gynecol. 1971;110:773781.
48. Zuna RE, Behrens A. Peritoneal washing cytology in gynecologic cancers: long-term follow-up of 355 patients. J Natl
Cancer Inst. 1996;88:980987.
49. Pectasides D, Pectasides E, Psyrri A, et al. Treatment issues
in clear cell carcinoma of the ovary: a different entity?
Oncologist. 2006;11:10891094.
50. Baak JP, Langley FA, Talerman A, et al. Interpathologist
and intrapathologist disagreement in ovarian tumor
grading and typing. Anal Quant Cytol Histol. 1986;8:354
357.
51. Hernandez E, Bhagavan BS, Parmley TH, et al. Interobserver variability in the interpretation of epithelial ovarian
cancer. Gynecol Oncol. 1984;17:117123.
52. Kodama S, Tanaka K, Tokunaga A, et al. Multivariate analysis of prognostic factors in patients with ovarian cancer
stage I and II. Int J Gynaecol Obstet. 1997;56:147153.